| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_KLHL2_0005800 | Exon-Exon | chr4:166234411-166235284 | chr4:165313259-165314132 | 215 nt | 0.4326 |
| hsa_KLHL2_0005900 | Exon-Exon | chr4:166235178-166235318 | chr4:165314026-165314166 | 141 nt | 0.4113 |
| hsa_KLHL2_0006000 | Exon-Exon | chr4:166235292-166239094 | chr4:165314140-165317942 | 144 nt | 0.4028 |
| hsa_GK3P_0000100 | Intergenic-Exon-Intergenic | chr4:166184484-166226856 | chr4:165263332-165305704 | 502 nt | 0.4502 |
A study in humans identified the circKLHL2 as a potential biomarker for immune-mediated demyelinating disease, where its levels in cerebrospinal fluid exosomes were specifically characterized [Misir et al. DOI:10.1038/s41418-022-00948-7]. A study in mice and human patients demonstrated that the circKLHL2 may expedite sepsis-induced acute lung injury by adjusting the miR-29b-3p/ROCK axis [Xu et al. DOI:10.1080/01902148.2024.2429184].